INS and breast carcinoma: In other words, blocking the MAP kinase pathway could potentially stop cell growth while leaving the metabolic actions of the hormone unaffected, which would be particularly relevant in cases of breast cancer or colorectal cancer, where insulin promotes cell growth and proliferation in malignant clones.